Department of Gastroenterology, Shenzhen Longhua District Central Hospital, Shenzhen 518110, China.
Institute for Brain Research and Rehabilitation, South China Normal University, Guangzhou 510631, China.
Cancer Treat Rev. 2024 Jul;128:102763. doi: 10.1016/j.ctrv.2024.102763. Epub 2024 May 16.
The intricate epigenetic landscape of hepatocellular carcinoma (HCC) is profoundly influenced by alterations in DNA methylation patterns. Understanding these alterations is crucial for unraveling the molecular mechanisms underlying HCC pathogenesis. Methylated circulating tumor DNA (ctDNA) presents itself as an encouraging avenue for biomarker discovery and holds substantial clinical implications in HCC management. This review comprehensively outlines the studies concerning DNA methylation in HCC and underscores the significance of methylated ctDNA within this context. Moreover, a variety of cfDNA methylation-based methodologies, such as 5hmC profiling, bisulfite-based, restriction enzyme-dependent, and enrichment-based methods, provide in-depth insights into the molecular pathology of HCC. Additionally, the integration of methylated ctDNA analysis into clinical practice represents a significant advancement in personalized HCC management. By facilitating cancer screening, prognosis assessment, and treatment response prediction, the utilization of methylated ctDNA signifies a pivotal stride toward enhancing patient care and outcomes in HCC.
肝细胞癌 (HCC) 中复杂的表观遗传景观受到 DNA 甲基化模式改变的深刻影响。了解这些改变对于揭示 HCC 发病机制的分子机制至关重要。甲基化的循环肿瘤 DNA (ctDNA) 作为生物标志物发现的一个有希望的途径出现，并在 HCC 管理中具有重要的临床意义。本综述全面概述了 HCC 中 DNA 甲基化的研究，并强调了甲基化 ctDNA 在这方面的重要性。此外，各种基于 cfDNA 甲基化的方法，如 5hmC 分析、亚硫酸氢盐法、依赖限制酶的方法和富集法，深入了解 HCC 的分子病理学。此外，将甲基化 ctDNA 分析纳入临床实践是 HCC 个体化管理的重大进展。通过促进癌症筛查、预后评估和治疗反应预测，甲基化 ctDNA 的利用标志着提高 HCC 患者护理和结果的重要一步。
